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Angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) are considered stan-
dard therapies in patients with certain comorbid conditions,
such as coronary artery disease and congestive heart failure,
because of their favorable impact on mortality and cardio-
vascular outcomes (4–6). Although these agents are also
deemed beneﬁcial toward delaying progression of kidney
disease in patients with nondialysis-dependent CKD (7–13),
their effects on mortality in this patient population remain
unclear.
See page 659
Observational studies examining the effect of ACEI or
ARB on mortality in CKD of various stages have yielded
Abbreviations
and Acronyms
ACEI = angiotensin-
converting enzyme inhibitor
ARB = angiotensin receptor
blocker
CHF = congestive heart
failure
CKD = chronic kidney
disease
eGFR = estimated
glomerular ﬁltration rate
OR = odds ratio
RCT = randomized controlled
trial
JACC Vol. 63, No. 7, 2014 Molnar et al.
February 25, 2014:650–8 ACEI and ARB and Mortality in Chronic Kidney Disease
651inconclusive results, with some (14–21) but not all (22)
showing an association with lower mortality. Most of these
studies enrolled patients from single centers (18,20,21) or
limited geographic areas (14,17), and many were limited to
patients with certain comorbid characteristics, such as
congestive heart failure (CHF), coronary artery disease
(CAD), and diabetes (14–16,18–20,22), making it difﬁcult
to generalize their results to the entire population with
CKD. Moreover, randomized controlled trials (RCTs) of
ACEI and/or ARB in CKD also do not offer a clear answer
regarding their effect on mortality. A recent meta-analysis of
RCTs that examined the effect of ACEI and ARB on all-
cause mortality in patients with early-stage (stages 1 to 3)
CKD (23) identiﬁed only 3 studies (11,24,25) and concluded
that the evidence was insufﬁcient to determine whether ACEI
or ARB is beneﬁcial in this population. Clinical trials of ACEI
and/or ARB that included patients with CKD with more
advanced stages examined primarily renal and composite renal
outcomes (which sometimes included mortality), but not
mortality alone (7–10,13,26). An earlier meta-analysis of
smaller RCTs examining primarily the effect of ACEI on the
progression of CKD in nondiabetic patients did not detect
a signiﬁcant effect on mortality, but there were only 29 deaths
in the 10 studies included in this analysis (12).
Given the uncertainty surrounding the effect of ACEI/
ARB administration on mortality in patients with CKD, we
examined this question in a large, nationally representative
cohort of U.S. veterans with nondialysis-dependent CKD.
We hypothesized that ACEI/ARB administration is associ-
ated with a lower risk of mortality in this patient population.Methods
Cohort deﬁnition. A detailed description of our non-
dialysis-dependent CKD cohort has been published (27,28).
Brieﬂy, glomerular ﬁltration rate was estimated from serum
creatinine measurements and demographic characteristics by
the Chronic Kidney Disease Epidemiology Collabora-
tion equation (29), and CKD was deﬁned on the basis of
the presence of a stable estimated glomerular ﬁltration
rate (eGFR) <60 ml/min/1.73 m2 or a stable eGFR 60
ml/min/1.73 m2 and an elevated urine microalbumin
measurement (30). We identiﬁed exposure to ACEI and/or
ARB on the basis of VA Outpatient Pharmacy dispensation
records (31). Patients who received at least 1 dispensation of
ACEI or ARB in a calendar quarter were recorded as having
been treated with these agents. Most patients received 90-
day supplies of ACEIs/ARBs (81% of all pharmacy
dispensations), and almost all received at least a 30-day
supply (98% of dispensations). The algorithm for deﬁning
the cohort used for the present study is shown in Online
Figure S1. Of a total of 659,546 patients with nondialysis-
dependent CKD between October 1, 2004, and September
30, 2006 (27), we identiﬁed 194,175 patients who were
not treated with an ACEI/ARB before entering the
cohort, on the basis of a review of VA OutpatientPharmacy dispensation records
from October 1, 2002, to
September 30, 2004. For our
analysis, we deﬁned de novo ex-
posure as the initiation of ACEI
or ARB in previously untreated
patients within 1 year of entering
the CKD cohort to minimize
secular trends in prescribing prac-
tices. Patients were categorized as
untreated if they did not receive
any ACEI or ARB throughout
the duration of the follow-up
period. After excluding patients
who initiated ACEI or ARB
>1 year after entering the CKD
cohort (n ¼ 31,509) and patients with incomplete information
on ACEI/ARB treatment (n ¼ 21,253), our cohort consisted
of 141,413 patients (26,051 in the treated group and 115,362
in the untreated group). To minimize confounding by indi-
cation (32), we generated from this group a propensity score-
matched cohort of 40,494 patients (20,247 exposed and
20,247 unexposed to ACEI/ARB) for our primary analyses.
Sociodemographic characteristics, comorbidities, and
laboratory characteristics. Data on patient age, sex, race,
and blood pressure were obtained through the VA Corpo-
rate Data Warehouse. Information on race was com-
plemented with data obtained from Medicare through the
VA-Medicare data merge project (33). All blood pressure
values available from the October 1, 2004, to October 1,
2009, time period were recorded and grouped by calendar
quarters, and their quarterly averaged values were used for
analyses (34). Data on comorbidities and the occurrence of
episodes of acute kidney injury were collected from the VA
Inpatient and Outpatient Medical SAS Datasets (35) using
International Classiﬁcation of Diseases, Ninth Revision
diagnostic and procedure codes and Current Procedural
Terminology codes recorded during the October 1, 2004, to
September 30, 2006, time period. Prevalent cardiovascular
disease was deﬁned as the presence of diagnostic codes for
coronary artery disease, angina, or myocardial infarction, or
procedure codes for percutaneous coronary interventions
or coronary artery bypass grafting. We calculated the
Charlson Comorbidity Index using the Deyo modiﬁcation
for administrative datasets, without including kidney disease
(36,37). Data on select laboratory variables were collected
from October 1, 2004, to September 30, 2009, using the
Decision Support System National Data Extracts Labora-
tory Results ﬁle (38). To minimize random variability, all
available laboratory values were grouped by calendar quar-
ters, and their quarterly averaged values were used in anal-
yses. We used Medicare and Medicaid deﬁnition for race
categories (39).
Outcomes. Information about all-cause mortality was
obtained from the VA Vital Status Files. The VA Vital
Status Files is a registry containing dates of death or last
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in the VA system with a sensitivity and speciﬁcity compared
with the National Death index as the gold standard of
98.3% and 99.8%, respectively (40).
Statistical analyses. Descriptive analyses were performed,
and skewed variables were log-transformed. In the cohort of
141,413 patients, data were missing for marital status
(1.4%), blood pressure (4.5%), eGFR (1.5%), and serum
potassium (1.7%), with 93% of patients having complete
data. Missing values were not imputed in primary analyses
and were substituted by using single imputation procedures
in sensitivity analyses.
The start of the follow-up period for both treated and
untreated patients was the date of cohort entry. Patients ﬁrst
exposed to an ACEI/ARB at a subsequent date were
considered as part of the untreated group for the time period
between cohort entry and ACEI/ARB initiation in all
survival analyses. Patients were followed until death or were
censored at the date of the last health care or administrative
VA encounter or on September 30, 2009.
The propensity score method was used to account for the
confounding arising from the differences in the clinical
characteristics of patients initiating ACEI/ARB versus the
untreated group. This method allows for the generation of
a single variable representing the likelihood of an individual
patient’s ACEI/ARB use based on the presence or absence
of deﬁned clinical characteristics in each individual. Patients
with and without exposure to ACEI/ARB can then be
matched on the basis of similar propensity scores to ensure
that the typical predictors of therapy with these agents
are similar in the 2 groups, and are thus not confounding
the association of ACEI/ARB therapy with the studied
outcome. Variables associated with ACEI/ARB adminis-
tration were identiﬁed using logistic regression and were
used to calculate propensity scores of the likelihood
of initiating ACEI/ARB (41). C-statistic and receiver-
operating characteristic analysis was used to test the logistic
regression model. A propensity score-matched cohort was
generated by a 1-to-1 nearest neighbor matching without
replacement using Stata’s “psmatch2” command suite (Sta-
taCorp LP, College Station, Texas).
The association of ACEI/ARB administration with
mortality was assessed using the Kaplan-Meier method.
ACEI/ARB administration was modeled in both an
“intention-to-treat” approach (with all de novo exposed
patients kept in the treated group irrespective of subsequent
discontinuation of ACEI/ARB) and an “as-treated” approach
(with patients allowed to switch treatment groups in time-
dependent analyses according to actual subsequent exposure
status). We hypothesized that change in certain clinical
characteristics arising as a result of ACEI/ARB therapy
(e.g., hyperkalemia, low blood pressure, or decline in kidney
function) could result in subsequent discontinuation of
ACEI/ARB therapy. These clinical characteristics can thus
be both time-dependent confounders in that they cause
a change in initially assigned ACEI/ARB therapy andintermediate variables in that they could be the mediators
of ACEI/ARB effect on outcomes. Simple adjustment
for these characteristics in multivariable models results
in biased estimates. Novel classes of statistical methods are
marginal structural models, which address the problem of
time-dependent confounding by inverse probability weight-
ing for receipt of the intervention (42–43). Stabilized
inverse probability of treatment weights for ACEI/ARB
use were calculated using baseline covariate values (age, sex,
race, marital status, type of insurance, presence of cardiovas-
cular disease, CHF, hypertension, diabetes mellitus, liver
disease, rheumatologic disease, lung disease, malignancy,
depression, dementia, and Charlson Comorbidity Index)
and time-varying covariate values (systolic and diastolic
blood pressures, eGFR, and serum potassium). To account
for selection bias, inverse probability of censoring weights
was calculated and combined with the inverse probability
of treatment weights. The mortality risk associated with
time-dependent ACEI/ARB use was then assessed in a
weighed generalized linear model with binary outcomes.
The association of ACEI/ARB administration with
mortality was examined separately in subgroups of patients
categorized by eGFR level, key sociodemographic charac-
teristics, presence or absence of key comorbid conditions,
and their levels of relevant laboratory and blood pressure
values. Sensitivity analyses were performed by examining the
entire cohort of 141,413 patients and calculating a propen-
sity score that also included levels of microalbuminuria.
Finally, we repeated our analyses after imputing missing
independent variables (<7%).
Statistical analyses were performed using Stata MP
version 11.1 (StataCorp LP). The study protocol was
approved by the Research and Development Committee at
the Memphis VA Medical Center.Results
Baseline characteristics. The age of the cohort at baseline
was 74.8  9.8 years; 89% and 8% of patients were white
and black, respectively; 22% of the patients were diabetic;
and the mean eGFR was 50  13 ml/min/1.73 m2. During
the ﬁrst year after entering the cohort, 18% (n ¼ 26,051) of
patients started ACEI/ARB therapy. Baseline characteristics
of patients categorized by ACEI/ARB use in the ﬁrst year
of follow-up are shown in Table 1. Patients treated with
ACEI/ARB were younger, more likely to be black, and
more likely to have diabetes, hypertension, congestive heart
failure (CHF), cardiovascular disease, and higher eGFR and
systolic and diastolic blood pressures. Online Table S1
shows the baseline characteristics of patients included in
our ﬁnal cohort versus those excluded for reason of prior
exposure to ACEI/ARB or missing information regarding
exposure to ACEI/ARB. Excluded patients were younger,
more likely to be black and diabetic, and more likely to
have hypertension, cardiovascular disease, CHF, and higher
systolic blood pressure.
Table 1 Baseline Characteristics of Individuals Stratiﬁed by ACEI/ARB Exposure
Total Cohort
(N ¼ 141,413)
ACEI/ARB Treated
(n ¼ 26,051)
Untreated
(n ¼ 115,362) p Value*
Male 97% 97% 96% <0.001
Age (yrs) 74.8  9.8 73.1  10.3 75.2  9.7 <0.001
Deaths 39,556 (28%) 6,484 (25%) 33,072 (29%) <0.001
Race <0.001
White 89% 85% 90%
African American 8% 10% 7%
Hispanic 1% 1% 1%
Other 2% 4% 2%
Diabetes mellitus 22% 41% 17% <0.001
eGFR (ml/min/1.73 m2) 50  13 52  16 50  12 <0.001
CKD <0.001
Stage 1 1% 4% 1%
Stage 2 3% 6% 2%
Stage 3A 69% 62% 71%
Stage 3B 21% 22% 20%
Stage 4 5% 5% 5%
Stage 5 1% 1% 1%
Blood pressure (mm Hg)
Systolic 133  17 138  18 132  16 <0.001
Diastolic 72  10 74  11 72  10 <0.001
BMI (kg/m2) 27.9  5.1 29.0  5.5 27.5  5.0 <0.001
Comorbidities
Hypertension 71% 89% 67% <0.001
Cardiovascular disease 34% 43% 32% <0.001
Congestive heart failure 8% 14% 6% <0.001
Cerebrovascular disease 12% 15% 12% <0.001
Chronic lung disease 24% 25% 24% 0.005
Liver disease 1% 1% 1% 0.014
Rheumatologic disease 2% 2% 2% <0.001
Cancer 20% 18% 21% <0.001
Depression 7% 7% 7% 0.016
Charlson Comorbidity Index 3 (2–4) 3 (2–4) 3 (2–4) <0.001
Laboratory values
Serum potassium 4.3  0.5 4.3  0.5 4.3  0.5 0.932
Spot urine microalbumin/creatinine 33 (9–68) 41 (15–85) 29 (7–58) <0.001
Serum albumin (g/dl) 3.97  0.43 3.99  0.42 3.97  0.43 <0.001
Blood hemoglobin (g/dl) 14.1  1.7 14.1  1.7 14.1  1.7 0.987
Serum cholesterol (mg/dl) 175  38 174  40 175  37 <0.001
Serum calcium (mg/dl) 9.3  0.5 9.3  0.5 9.3  0.5 0.389
Serum bicarbonate (mmol/l) 27.4  3.0 27.4  3.0 27.4  2.9 0.287
WBC count (103/l) 7.4  5.3 7.4  3.0 7.4  5.7 0.991
Values are %, mean  SD, n (%), or median (IQR). ACEI/ARB exposure was deﬁned as de novo initiation of any ACEI or ARB during the ﬁrst year of
follow-up. Unexposed patients were deﬁned as those not receiving any ACEI or ARB throughout the entire follow-up period. *p value compares the
treated and untreated groups.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; CKD ¼ chronic kidney disease;
eGFR ¼ estimated glomerular ﬁltration rate; IQR ¼ interquartile range; WBC ¼ white blood cell.
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653Table 2 shows the baseline characteristics of the treated
and untreated groups in the propensity score-matched
cohort, which showed only clinically minor differences,
albeit most of these were statistically signiﬁcant because of
the large sample size.
Likelihood of initial ACEI/ARB exposure. Table 3
shows the multivariable adjusted odds ratios (ORs) of
initiating ACEI/ARB treatment during the ﬁrst year of
the follow-up period associated with various baselinecharacteristics. Diabetic and hypertensive patients and those
with CHF were more than twice as likely to initiate treat-
ment compared with patients without these conditions.
Furthermore, each 10 ml/min/1.73 m2 higher eGFR and 10
mm Hg higher systolic blood pressure were associated with
a 13% and 22% higher likelihood of initiating treatment,
respectively. The area under the receiver-operating charac-
teristic of the predicted probability of ACEI/ARB admin-
istration in our logistic regression model was 0.74.
Table 2
Baseline Characteristics of Propensity Score-Matched
Cohort Stratiﬁed by ACEI/ARB Treatment Status
During the First Year of the Cohort
ACEI/ARB
Treated Untreated p Value*
n 20,247 20,247 N/A
Male 97% 97% 0.277
Age (yrs) 73.1  10.4 73.6  10.2 <0.001
Deaths 5,028 (25%) 6,450 (32%) <0.001
Race 0.007
White 84% 86%
African American 11% 10%
Hispanic 1% 1%
Other 4% 3%
Diabetes mellitus 41% 41% 0.425
eGFR (ml/min/1.73 m2) 52  16 51  15 <0.001
CKD
Stage 1 4% 3% <0.001
Stage 2 6% 5%
Stage 3A 62% 65%
Stage 3B 22% 20%
Stage 4 5% 6%
Stage 5 1% 1%
Blood pressure (mm Hg)
Systolic 138  18 138  17 0.016
Diastolic 74  11 73  11 <0.001
Comorbidities
Hypertension 89% 90% <0.001
Cardiovascular disease 43% 44% <0.001
Congestive heart failure 14% 15% 0.631
Cerebrovascular disease 15% 14% <0.001
Chronic lung disease 26% 26% 0.786
Liver disease 1% 1% <0.001
Rheumatologic disease 2% 2% 0.052
Malignancy 18% 21% <0.001
Depression 7% 7% 0.336
Charlson Comorbidity Index 3 (2–5) 3 (2–5) <0.001
Laboratory values
Serum potassium (mmol/l) 4.3  0.5 4.3  0.5 0.133
Spot urine microalbumin/
creatinine
42 (15–86) 34 (10–71) <0.001
Serum albumin (g/dl) 3.98  0.43 3.97  0.45 0.058
Blood hemoglobin (g/dl) 14.0  1.7 14.0  1.8 <0.001
Serum cholesterol (mg/dl) 173  40 172  39 0.013
Serum calcium (mg/dl) 9.3  0.5 9.3  0.5 0.357
Serum bicarbonate (mmol/l) 27.4  3.0 27.5  3.0 0.021
WBC (103/l) 7.4  3.1 7.5  4.7 0.004
Values are n (%), mean  SD, or median (IQR). *p value compares the treated and untreated
groups.
N/A ¼ not applicable; other abbreviations as in Table 1.
Table 3
ORs (95% CIs) of ACEI/ARB Initiation During the
First Year of the Cohort
OR 95% CI p Value
Age (each þ10 yrs) 0.80 0.78–0.81 <0.001
Race
White (reference) 1.00 1.00–1.00 N/A
African American 1.09 1.03–1.15 0.002
Hispanic 1.41 1.22–1.62 <0.001
Other race 1.20 1.04–1.38 0.01
Female (vs. male) 0.84 0.76–0.92 <0.001
Presence of diabetes mellitus
(vs. absence of diabetes mellitus)
2.73 2.63–2.83 <0.001
eGFR (each þ10 ml/min/1.73 m2) 1.13 1.12–1.15 <0.001
Systolic blood pressure
(each þ10 mm Hg)
1.22 1.21–1.24 <0.001
Presence of cardiovascular diseases
(vs. absence of cardiovascular
disease)
1.44 1.39–1.49 <0.001
Presence of hypertension
(vs. absence of hypertension)
3.15 3.00–3.30 <0.001
Presence of congestive heart failure
(vs. absence of congestive heart
failure)
2.27 2.15–2.39 <0.001
Serum potassium (each þ1 mmol/l) 1.11 1.07–1.15 <0.001
The ORs of ACEI/ARB initiation are calculated from a multivariable logistic regression model.
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Table 1.
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quartile range: 3.6 to 5.2 years). In the propensity score-
matched cohort, there were 5,028 deaths (25%, mortality
rate [95% CI] 22.6 [22.0 to 23.2]/1,000 patient-years) in
the treated group and 6,450 deaths (32%, 26.5 [25.9 to
27.2]/1,000 patient-years) in the untreated group. Of
20,247 patients initiating ACEI/ARB, 1,705 (8.4%), 3,385
(17%), and 13,353 (66%) received their medication 100%,>90%, and >50% of time during follow-up visits,
respectively.
Figure 1 shows the survival probability of treated and
untreated patients in the propensity score-matched cohort,
with ACEI/ARB treatment showing an association with
lower mortality in both intention-to-treat and as-treated
models. Similar associations are shown in Online Figure S2,
which shows the cumulative hazards of treated and untreated
patients in the propensity score-matched cohort. ACEI/
ARB administration was associated with a lower risk of
mortality in both the intention-to-treat analysis (hazard ratio:
0.81, 95% conﬁdence interval [CI]: 0.78 to 0.84) and the
as-treated analysis (OR: 0.37, 95% CI: 0.34 to 0.41). The
estimated mortality risk associated with ACEI/ARB treat-
ment was lower in all examined subgroups, but a lower
magnitude of beneﬁt was observed in nondiabetic patients
(Fig. 2). The beneﬁt associated with ACEI/ARB use was
independent of eGFR level.
We performed a sensitivity analysis using the cohort of
172,922 patients (the 141,413 patients in the original
analysis and 31,509 patients who started ACEI/ARB >1
year after the cohort entry). By using this cohort, ACEI/
ARB administration was associated with a lower risk of
mortality in both the intention-to-treat analysis (hazard
ratio: 0.66, 95% CI: 0.64 to 0.68) and the as-treated
analysis (OR: 0.48, 95% CI: 0.44 to 0.52). Hazard ratios
and ORs of mortality associated with ACEI/ARB admin-
istration were similar when analyzing the entire cohort of
141,413 patients and when matching patients by
a propensity score that included microalbuminuria (results
Figure 1
Kaplan-Meier Survival Curves of 20,247 Patients Treated With ACEIs/ARBs and 20,247 Untreated Patients Matched by
Propensity Scores
Kaplan-Meier survival curves of 20,247 angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)-treated and 20,247 untreated patients matched
by propensity scores. Exposure modeled in intention-to-treat (A) and as-treated manner (B).
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655not shown). We also found qualitatively similar results
when repeating our analyses after imputing missing vari-
ables (not shown).
Discussion
We examined characteristics of de novo ACEI/ARB initia-
tion and their effect on all-cause mortality in a large cohort
of U.S. veterans with all stages of nondialysis-dependent
CKD.We found that traditional indications for ACEI/ARB
administration, such as higher blood pressure and con-
gestive heart failure, were associated with therapy initiation.
Administration of ACEI/ARB was associated with lower
all-cause mortality in various statistical analyses that adjusted
for bias by indication and for selective discontinuation
of ACEI/ARB therapy. In these nondialysis-dependent
patients with CKD, discontinuation rates of ACEI/ARB
were high: only 66% of treated patients received renewed
prescriptions on >50% of their follow-up visits, and
only <10% of patients remained on ACEI/ARB therapy
throughout all follow-up visits. Because of such high
discontinuation rates, it is possible that the 19% lower
mortality associated with ACEI/ARB administration in
intention-to-treat analyses (in which all patients are con-
sidered as receiving treatment throughout follow-up irre-
spective of discontinuation of the drug) is underestimating
the true effect of these medications. Consistent with this
hypothesis, the beneﬁt of ACEI/ARB appeared larger in as-
treated exposure models. Our result remained qualitatively
unchanged even when using marginal structural models to
account for the selective discontinuation of these agents due
to hyperkalemia, hypotension, or change in kidney function.
In addition, patients treated with ACEI/ARB in our study
were more likely to be black and to have diabetes, hyperten-
sion, congestive heart failure, cardiovascular disease, and
higher systolic and diastolic blood pressures. As a result,the risk of mortality is expected to be higher in these patients.
The fact that ACEI/ARB use was associated with lower
mortality despite this imbalance further strengthens our
conclusion that ACEI/ARB treatment might be protective.
However, the main reason for using a propensity score-
matched analysis is to eliminate this type of bias by creating
2 groups for comparison with similar comorbid and other
relevant conditions. The fact that even after propensity
score matching, patients treated with ACEI/ARB reported
better outcomes also supports our conclusions.
The uncertainty surrounding the effects of ACEI/ARB
on mortality in nondialysis-dependent CKD stems from the
paucity of clinical trials with a mortality endpoint in this
patient population. Previous large RCTs of ACEI/ARB in
CKD primarily explored renal endpoints (8–10,24,26), and
other studies initiated to determine the effects of ACEI/
ARB on mortality have typically excluded patients with
moderate or advanced CKD (23). Extrapolating the results
of studies from the general population to patients with
CKD may be inappropriate given potentially harmful
CKD-speciﬁc effects of ACEI/ARB, such as hyperkalemia
or acute kidney injury (44). Given the paucity of clinical trial
evidence, the association of ACEI/ARB administration
with mortality in CKD has been explored in a number of
observational studies, with most (14–21) but not all (22)
showing beneﬁcial trends. However, to the best of our
knowledge, our study is the only one that examines a large
cohort of patients with nondialysis-dependent CKD with
de novo exposure to ACEI/ARB without restricting enroll-
ment on the basis of geographic location, hospitalization, or
other preexisting comorbid conditions. Our study suggests
a substantial survival beneﬁt from ACEI/ARB administra-
tion in nondialysis-dependent patients with CKD even when
applying novel statistical techniques that can better control for
confounding, such as propensity score matching and inverse
probability treatment weighing (42,45).
Figure 2
Hazard Ratios (95% CIs) of All-Cause Mortality Associated With ACEI/ARB Administration in Various Subgroups of
40,494 Propensity Score-Matched Patients With Nondialysis-Dependent CKD
Results are from unadjusted time-dependent Cox analyses modeling ACEI/ARB exposure in intention-to-treat manner. ACR ¼ urine albumin creatinine ratio; BP ¼ blood
pressure; CHF ¼ congestive heart failure; CI ¼ conﬁdence interval; CKD ¼ chronic kidney disease; eGFR ¼ estimated glomerular ﬁltration rate; other abbreviations as in
Figure 1.
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656Several potential mechanisms can explain the association
between ACEI/ARB administration and decreased risk of
mortality. ACEI/ARB treatment decreases the severity of
left ventricular hypertrophy (46), dilation (47), remodeling,
and heart failure (48) commonly seen in CKD, and their
treatment could contribute to lower cardiovascular risk. In
addition, ACEIs/ARBs are renoprotective in patients with
CKD, which could indirectly provide survival beneﬁts
(8–10,24). ACEI/ARB administration was associated with
a substantially larger survival beneﬁt in diabetic patients
compared with nondiabetic patients. Patients with cardiovas-
cular disease, heart failure, and hypertension may overpopu-
late the diabetic cohort, thus resulting in the larger apparent
beneﬁt from ACEI/ARB treatment in this subgroup.
Another potential mechanism is the anti-inﬂammatory
effect of renin-angiotensin system modulation, which could
be especially important in this group of patients in whominﬂammation is likely more prevalent than in non-CKD
populations (49–51).
It is important to note that approximately 30% of our
original cohort had not been exposed to an ACEI/ARB.
Our data cannot provide deﬁnitive answers to why these
patients were not treated with ACEIs/ARBs, but some
potential explanations can be proposed. Patients previously
exposed to ACEIs/ARBs were younger, more likely to be
black and diabetic, and more likely to have hypertension,
cardiovascular disease, CHF, and higher systolic blood
pressure. These patients were “sicker” and more likely to
have comorbidities, such as CHF and diabetes, which are
well-documented indications of ACEI/ARB initiation. It is
possible that patients who were previously unexposed to an
ACEI/ARB and were subsequently administered these
agents developed such indications de novo, which then led
to the initiation of these medications. It is also possible
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657that patients never exposed to such agents did not have
a solid indication for them or had contraindications to them.
Study strengths and limitations. Our study is notable for
its large sample size and event numbers, and for being
representative of veterans in the entire geographic United
States. Our study also has limitations that need to be
acknowledged. A limitation of observational studies such as
ours is that they cannot prove causal associations between
predictors and outcomes, and therefore we cannot claim
that the administration of ACEI/ARB was indeed the
primary reason for the better survival observed in the group
exposed to these agents (32). We used relatively novel
statistical methods, such as propensity score matching
and marginal structural modeling, to minimize the effects
of bias by indication and time-dependent confounding
(42,45), but even these methods do not address unmeasured
confounders. Full endorsement of the clinical use of ACEIs/
ARBs toward decreasing mortality will thus be possible only
if our results are corroborated by clinical trials. The study
population consisted mostly of male patients; thus, the
results may not apply to female patients. In addition, our
results cannot be applied to patients receiving renal
replacement therapy. We used data obtained during the
course of clinical practice, making selection bias by medical
indication possible. However, we used serum creatinine-
based equations for cohort deﬁnition, which is part of rou-
tine panels that are measured in most patients receiving
health care; it is thus less likely that a large proportion of
actively enrolled veterans were excluded. We deﬁned CKD
using the Chronic Kidney Disease Epidemiology Collabo-
ration equation because it is more accurate than other esti-
mating equations (e.g., Modiﬁcation of Diet in Renal
Disease equation) in patients with normal and mildly
decreased glomerular ﬁltration rate (52). We did not collect
information about other clinically relevant outcomes, such
as end-stage renal disease and hospitalizations; thus, we
could not test the association of ACEI/ARB with such
outcomes, and we could not determine whether their effect
on mortality is different before or after initiating dialysis
therapy. In addition, we did not have information about the
causes of death; therefore, we cannot analyze associations
with cardiovascular mortality, and we did not collect infor-
mation about smoking history. Nevertheless, by examining
overall (pre- and post-dialysis) mortality, we eliminated
the potential bias imparted by the competing risk of end-
stage renal disease as an endpoint. We did not examine
the effects of other antihypertensive agents; thus, we cannot
determine to what extent the observed effects of ACEIs/
ARBs were related to blood pressure lowering, to some
other physiologic effect of this drug class, or merely to the
fact that patients administered such medications may have
received better care in general. However, we were able to
match treated and untreated patients closely for their blood
pressure levels, which would partially alleviate this concern.
Last, we used diagnostic codes to deﬁne comorbid condi-
tions that could act as confounders in the association ofACEI/ARB initiation with lower mortality risk, which
may have resulted in underestimation of their prevalence.
Conclusions
In our large and contemporary cohort of 141,413 nondialysis-
dependent patients with CKD, ACEI/ARB administration
was associated with improved survival. Given the high
mortality rates observed in patients with nondialysis-
dependent CKD, the paucity of interventions available to
lower these mortality rates, and the difﬁculties associated
with conducting properly powered RCTs in this population,
our results may have important clinical and public health
implications by suggesting that ACEIs/ARBs may hold
beneﬁts beyond renoprotection in this vulnerable population
and by re-emphasizing the need for RCTs with a mortality
endpoint.
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